Latus Bio has secured $42 million in funding as it prepares to seek regulatory clearance for a clinical trial of its gene therapy for Huntington's disease. The financing will support the company's efforts to move the experimental treatment into human studies.
Huntington's disease is a rare, inherited neurodegenerative disorder that currently has no cure. The gene therapy approach aims to address the underlying genetic cause, offering a potential disease-modifying treatment for patients who have limited options today.
The $42 million raise positions Latus Bio to initiate the complex process of filing an investigational new drug application with the FDA. The company will need to demonstrate preclinical safety and efficacy data to gain approval for first-in-human testing.
If the trial proceeds, it could mark a significant step forward for Huntington's patients and the broader gene therapy field, which has faced challenges with delivery and durability. Success would validate Latus Bio's platform and potentially attract additional investment.
Gene therapies remain a high-risk, high-reward area of drug development, with several previous attempts failing to meet endpoints. The company's approach will need to overcome these historical hurdles.